Cite
HARVARD Citation
Laffel, L. et al. (2023). Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet. 11 (3), pp. 169-181. [Online].